Morgan Stanley Larimar Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 169,038 shares of LRMR stock, worth $625,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

169,038

Previous 411,380 58.91%

Holding current value

$625,440

Previous $884,000 44.8%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$1.71 - $3.25 $414,404 - $787,611	-242,342 Reduced 58.91%	169,038 $488,000
Q1 2025 May 15, 2025	BUY	$2.15 - $4.18 $518,582 - $1.01 Million	241,201 Added 141.73%	411,380 $884,000
Q4 2024 Feb 14, 2025	BUY	$3.8 - $9.29 $79,613 - $194,634	20,951 Added 14.04%	170,179 $650,000
Q3 2024 May 14, 2025	BUY	$6.3 - $10.68 $602,374 - $1.02 Million	95,615 Added 178.34%	149,228 $977,000
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $602,374 - $1.02 Million	95,615 Added 178.34%	149,228 $977,000
Q2 2024 May 14, 2025	SELL	$6.33 - $9.89 $737,862 - $1.15 Million	-116,566 Reduced 68.5%	53,613 $388,000
Q2 2024 Oct 17, 2024	BUY	$6.33 - $9.89 $40,030 - $62,544	6,324 Added 13.37%	53,613 $388,000
Q2 2024 Aug 14, 2024	BUY	$6.33 - $9.89 $40,030 - $62,544	6,324 Added 13.37%	53,613 $388,000
Q1 2024 Oct 17, 2024	SELL	$4.2 - $13.28 $26,560 - $83,982	-6,324 Reduced 11.8%	47,289 $358,000
Q1 2024 Aug 16, 2024	SELL	$4.2 - $13.28 $37,485 - $118,524	-8,925 Reduced 15.88%	47,289 $358,000
Q1 2024 May 15, 2024	SELL	$4.2 - $13.28 $37,485 - $118,524	-8,925 Reduced 15.88%	47,289 $358,000
Q4 2023 Aug 16, 2024	BUY	$2.35 - $4.71 $6,112 - $12,250	2,601 Added 4.85%	56,214 $255,000
Q4 2023 Feb 13, 2024	BUY	$2.35 - $4.71 $74,918 - $150,154	31,880 Added 131.01%	56,214 $255,000
Q3 2023 Nov 15, 2023	SELL	$3.08 - $4.49 $24,800 - $36,153	-8,052 Reduced 24.86%	24,334 $96,000
Q2 2023 Aug 14, 2023	SELL	$3.13 - $5.27 $100,166 - $168,650	-32,002 Reduced 49.7%	32,386 $101,000
Q1 2023 May 15, 2023	SELL	$4.0 - $6.68 $1.91 Million - $3.18 Million	-476,449 Reduced 88.09%	64,388 $291,000
Q4 2022 Feb 14, 2023	BUY	$2.73 - $5.08 $28,785 - $53,563	10,544 Added 1.99%	540,837 $2.23 Million
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $742 - $1,765	485 Added 0.09%	530,293 $1.7 Million
Q2 2022 Oct 27, 2022	SELL	$1.9 - $3.98 $334 - $700	-176 Reduced 0.03%	529,808 $1.04 Million
Q2 2022 Aug 15, 2022	SELL	$1.9 - $3.98 $334 - $700	-176 Reduced 0.03%	529,808 $1.04 Million
Q1 2022 Oct 27, 2022	BUY	$3.65 - $10.84 $642 - $1,907	176 Added 0.03%	529,984 $2.15 Million
Q1 2022 May 13, 2022	BUY	$3.65 - $10.84 $1.89 Million - $5.62 Million	518,189 Added 4393.29%	529,984 $2.15 Million
Q4 2021 Feb 14, 2022	SELL	$8.86 - $13.47 $206,127 - $313,379	-23,265 Reduced 66.36%	11,795 $127,000
Q3 2021 Nov 15, 2021	BUY	$9.61 - $15.11 $336,926 - $529,756	35,060 New	35,060 $404,000

Others Institutions Holding LRMR

# of Institutions

128

Shares Held

66.1M

Call Options Held

4.83M

Put Options Held

83.7K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $160M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account